Madison Muller

They may be less effective after menopause.

Telehealth companies are aggressively marketing GLP-1s as cosmetic elixirs for anyone who wants to lose a few pounds.

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach that would bypass traditional drug sales channels in an effort to expand access to the costly weight-loss medicines.

The US Food and Drug Administration is rolling out a new program to speed up drug reviews by emphasizing clearer, more frequent communication with companies, aided by a surge of new hires.

Cheaper alternatives threaten its $2.7 billion treatment.

Competition and the “natural look” have created a perfect storm.

Cash-pay options will get cheaper as private insurers weigh costs for coverage.

Eli Lilly & Co. is dropping CVS Health Corp’s drug benefit plan for its employees after CVS stopped covering its blockbuster weight-loss drug in favor of a rival medication from Novo Nordisk A/S, according to people familiar with the matter.

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera Inc.

Hims & Hers Health Inc. rose after the telehealth company said it was in talks with Novo Nordisk A/S to sell its forthcoming obesity pill on the telehealth site.

Pfizer Inc. accused Novo Nordisk A/S of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera Inc., the second lawsuit Pfizer has filed in four days as it tries to retain its grip on a deal Novo upended last week.

Pfizer Inc. sued Metsera Inc. and rival drugmaker Novo Nordisk A/S to block the Danish company’s rival bid for the obesity startup.

Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat expectations in the third quarter and it began solidifying its lead over its biggest rival.

Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global demand ahead of a potential launch next year.

Verily, Alphabet Inc.’s life sciences unit, is launching a new AI-powered health app just months after the Trump administration encouraged tech companies to expand the suite of health-oriented tools available to consumers.

Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration launched an investigation into the medical device sector that could lead to tariffs on its biggest product category.

Novo Nordisk A/S plans to launch its new obesity pill on telehealth sites like Ro and WeightWatchers as soon as it’s approved. The move is an attempt to win back market share from rival Eli Lilly and Co., which has pulled ahead in the weight-loss drug race.

Tennis star’s 30-pound weight loss draws more attention to telehealth services

President Donald Trump announced a fresh round of tariffs on pharmaceuticals, heavy trucks and furniture, including a 100% duty on patented drugs unless the producer is building a manufacturing plant in the US.